Cargando…
Adjuvant Therapy: Melanoma
With an incidence that is increasing at 2–5% per year, cutaneous melanoma is an international scourge that disproportionately targets young individuals. Despite much research, the treatment of advanced disease is still quite challenging. Immunotherapy with high-dose interferon-α2b or interleukin-2 b...
Autores principales: | Davar, Diwakar, Tarhini, Ahmad, Kirkwood, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3246753/ https://www.ncbi.nlm.nih.gov/pubmed/22220281 http://dx.doi.org/10.1155/2011/274382 |
Ejemplares similares
-
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute
por: Davar, Diwakar, et al.
Publicado: (2017) -
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
por: Davar, Diwakar, et al.
Publicado: (2015) -
Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022) -
Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008) -
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
por: Eljilany, Islam, et al.
Publicado: (2023)